Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Other Accumulated Expenses (2022 - 2025)

Historic Other Accumulated Expenses for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to $450000.0.

  • BioXcel Therapeutics' Other Accumulated Expenses rose 8218.62% to $450000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $450000.0, marking a year-over-year increase of 8218.62%. This contributed to the annual value of $322000.0 for FY2024, which is 8192.09% up from last year.
  • As of Q3 2025, BioXcel Therapeutics' Other Accumulated Expenses stood at $450000.0, which was up 8218.62% from $366000.0 recorded in Q2 2025.
  • Over the past 5 years, BioXcel Therapeutics' Other Accumulated Expenses peaked at $832000.0 during Q3 2023, and registered a low of $177000.0 during Q4 2023.
  • In the last 4 years, BioXcel Therapeutics' Other Accumulated Expenses had a median value of $366000.0 in 2025 and averaged $424866.7.
  • Within the past 5 years, the most significant YoY rise in BioXcel Therapeutics' Other Accumulated Expenses was 11224.49% (2023), while the steepest drop was 7841.46% (2023).
  • Quarter analysis of 4 years shows BioXcel Therapeutics' Other Accumulated Expenses stood at $820000.0 in 2022, then crashed by 78.41% to $177000.0 in 2023, then skyrocketed by 81.92% to $322000.0 in 2024, then surged by 39.75% to $450000.0 in 2025.
  • Its Other Accumulated Expenses stands at $450000.0 for Q3 2025, versus $366000.0 for Q2 2025 and $423000.0 for Q1 2025.